Published in J Neural Transm (Vienna) on September 01, 2011
The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives. Chem Rev (2013) 0.98
Modeling Parkinson's disease in monkeys for translational studies, a critical analysis. Exp Neurol (2013) 0.94
The protein Ocular albinism 1 is the orphan GPCR GPR143 and mediates depressor and bradycardic responses to DOPA in the nucleus tractus solitarii. Br J Pharmacol (2014) 0.93
ABT-089 and ABT-894 reduce levodopa-induced dyskinesias in a monkey model of Parkinson's disease. Mov Disord (2014) 0.90
Multiple CNS nicotinic receptors mediate L-dopa-induced dyskinesias: studies with parkinsonian nicotinic receptor knockout mice. Biochem Pharmacol (2013) 0.90
Nicotine-mediated improvement in L-dopa-induced dyskinesias in MPTP-lesioned monkeys is dependent on dopamine nerve terminal function. Neurobiol Dis (2012) 0.88
α4β2 Nicotinic receptors play a role in the nAChR-mediated decline in L-dopa-induced dyskinesias in parkinsonian rats. Neuropharmacology (2013) 0.87
Levodopa/benserazide microspheres reduced levodopa-induced dyskinesia by downregulating phosphorylated GluR1 expression in 6-OHDA-lesioned rats. Drug Des Devel Ther (2012) 0.85
Nicotine reduces established levodopa-induced dyskinesias in a monkey model of Parkinson's disease. Mov Disord (2013) 0.84
Abnormal dopaminergic modulation of striato-cortical networks underlies levodopa-induced dyskinesias in humans. Brain (2015) 0.84
Controlled-release levodopa methyl ester/benserazide-loaded nanoparticles ameliorate levodopa-induced dyskinesia in rats. Int J Nanomedicine (2012) 0.84
Parallel dopamine D1 receptor activity dependence of l-Dopa-induced normal movement and dyskinesia in mice. Neuroscience (2013) 0.83
Nicotinic receptor agonists reduce L-DOPA-induced dyskinesias in a monkey model of Parkinson's disease. J Pharmacol Exp Ther (2013) 0.83
Intrastriatal injections of KN-93 ameliorates levodopa-induced dyskinesia in a rat model of Parkinson's disease. Neuropsychiatr Dis Treat (2013) 0.82
Metabotropic glutamate receptors for Parkinson's disease therapy. Parkinsons Dis (2013) 0.82
Brain morphometry and the neurobiology of levodopa-induced dyskinesias: current knowledge and future potential for translational pre-clinical neuroimaging studies. Front Neurol (2014) 0.81
Investigations into Potential Extrasynaptic Communication between the Dopaminergic and Nitrergic Systems. Front Physiol (2012) 0.81
Levodopa/benserazide microsphere (LBM) prevents L-dopa induced dyskinesia by inactivation of the DR1/PKA/P-tau pathway in 6-OHDA-lesioned Parkinson's rats. Sci Rep (2014) 0.80
Mechanisms underlying and medical management of L-Dopa-associated motor complications. J Neural Transm (Vienna) (2011) 0.79
Pharmacological Treatments Inhibiting Levodopa-Induced Dyskinesias in MPTP-Lesioned Monkeys: Brain Glutamate Biochemical Correlates. Front Neurol (2014) 0.79
Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia. Br J Pharmacol (2015) 0.78
Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients. Mov Disord (2016) 0.78
Corticostriatal Plastic Changes in Experimental L-DOPA-Induced Dyskinesia. Parkinsons Dis (2012) 0.77
Striatal molecular signature of subchronic subthalamic nucleus high frequency stimulation in parkinsonian rat. PLoS One (2013) 0.76
Neuroprotective effects of Eucommia ulmoides Oliv. and its bioactive constituent work via ameliorating the ubiquitin-proteasome system. BMC Complement Altern Med (2015) 0.75
Adenosine A2A Receptor Gene Knockout Prevents l-3,4-Dihydroxyphenylalanine-Induced Dyskinesia by Downregulation of Striatal GAD67 in 6-OHDA-Lesioned Parkinson's Mice. Front Neurol (2017) 0.75
The effect of piribedil on L-DOPA-induced dyskinesias in a rat model of Parkinson's disease: differential role of α(2) adrenergic mechanisms. J Neural Transm (Vienna) (2012) 0.75
Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med (2001) 9.51
Dopamine receptors: from structure to function. Physiol Rev (1998) 8.90
Endothelium-derived relaxing factor release on activation of NMDA receptors suggests role as intercellular messenger in the brain. Nature (1988) 8.56
The molecular logic of endocannabinoid signalling. Nat Rev Neurosci (2003) 7.78
Molecular basis of long-term plasticity underlying addiction. Nat Rev Neurosci (2001) 6.86
A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol (2003) 6.21
A review of central 5-HT receptors and their function. Neuropharmacology (1999) 6.13
Molecular interpretation of ERK signal duration by immediate early gene products. Nat Cell Biol (2002) 6.05
Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci (1991) 5.88
Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A (1990) 5.48
Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci U S A (1999) 5.11
Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med (1988) 4.98
D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons. Trends Neurosci (2007) 4.93
Modulation of striatal projection systems by dopamine. Annu Rev Neurosci (2011) 4.84
Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu Rev Pharmacol Toxicol (2010) 4.77
Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science (1999) 4.31
Endocannabinoid signaling in the brain. Science (2002) 4.28
Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature (1983) 4.24
Circuits and circuit disorders of the basal ganglia. Arch Neurol (2007) 3.97
Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci (1999) 3.45
Cellular and synaptic adaptations mediating opioid dependence. Physiol Rev (2001) 3.45
Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade. Neuron (1999) 3.36
Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci (2003) 3.25
Nitric oxide synthase and neuronal NADPH diaphorase are identical in brain and peripheral tissues. Proc Natl Acad Sci U S A (1991) 3.22
The neostriatal mosaic: multiple levels of compartmental organization in the basal ganglia. Annu Rev Neurosci (1992) 3.10
NMDA channel regulation by channel-associated protein tyrosine kinase Src. Science (1997) 3.01
Regulation of NMDA receptors by tyrosine kinases and phosphatases. Nature (1994) 2.96
Metabotropic glutamate receptors: electrophysiological properties and role in plasticity. Brain Res Brain Res Rev (1999) 2.95
Knockout of ERK1 MAP kinase enhances synaptic plasticity in the striatum and facilitates striatal-mediated learning and memory. Neuron (2002) 2.93
Highly potent and selective ligands for histamine H3-receptors. Nature (1987) 2.90
Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord (2001) 2.89
Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. Arch Neurol (2010) 2.64
Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res (2006) 2.62
Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology (1985) 2.58
The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurones. Trends Neurosci (1990) 2.54
Long-term synaptic depression in the striatum: physiological and pharmacological characterization. J Neurosci (1992) 2.54
Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain (2007) 2.49
Histochemical mapping of nitric oxide synthase in the rat brain. Neuroscience (1992) 2.38
Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors. Proc Natl Acad Sci U S A (2010) 2.36
Mu, delta, and kappa opioid receptor mRNA expression in the rat CNS: an in situ hybridization study. J Comp Neurol (1994) 2.33
The basal ganglia in Parkinson's disease: current concepts and unexplained observations. Ann Neurol (2008) 2.27
Characterization of protein kinase A and protein kinase C phosphorylation of the N-methyl-D-aspartate receptor NR1 subunit using phosphorylation site-specific antibodies. J Biol Chem (1997) 2.25
Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci (1997) 2.23
Bidirectional regulation of DARPP-32 phosphorylation by dopamine. J Neurosci (1997) 2.17
Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. J Neurosci (2007) 2.11
L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci (1998) 2.10
The central adrenergic system. An immunofluorescence study of the location of cell bodies and their efferent connections in the rat utilizing dopamine-beta-hydroxylase as a marker. J Comp Neurol (1975) 2.08
The evolution of diagnosis in early Parkinson disease. Parkinson Study Group. Arch Neurol (2000) 2.08
Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci (2001) 2.08
Genetic dissection of behavioural and autonomic effects of Delta(9)-tetrahydrocannabinol in mice. PLoS Biol (2007) 2.08
Opposing roles for D-1 and D-2 dopamine receptors in efflux of cyclic AMP from rat neostriatum. Nature (1981) 2.06
Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain. J Neurochem (2000) 2.04
Metabotropic glutamate receptors 1 and 5 differentially regulate CA1 pyramidal cell function. J Neurosci (2001) 2.03
Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur J Neurosci (2002) 2.01
D1 and D2 dopamine receptor gene expression in the rat striatum: sensitive cRNA probes demonstrate prominent segregation of D1 and D2 mRNAs in distinct neuronal populations of the dorsal and ventral striatum. J Comp Neurol (1995) 2.01
Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov Disord (2005) 2.01
Dopamine and cAMP-regulated phosphoprotein 32 kDa controls both striatal long-term depression and long-term potentiation, opposing forms of synaptic plasticity. J Neurosci (2000) 1.98
Adenosine A2A-dopamine D2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J Biol Chem (2003) 1.96
Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum. Brain Res Mol Brain Res (1992) 1.96
Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology (1998) 1.96
Levodopa-induced dyskinesias. Mov Disord (2007) 1.94
Excitatory amino acid receptors and synaptic plasticity. Trends Pharmacol Sci (1990) 1.90
Adenosine A2A receptors and basal ganglia physiology. Prog Neurobiol (2007) 1.90
Metabotropic glutamate receptors. Cell Tissue Res (2006) 1.89
Coaggregation, cointernalization, and codesensitization of adenosine A2A receptors and dopamine D2 receptors. J Biol Chem (2002) 1.88
Influence of phasic and tonic dopamine release on receptor activation. J Neurosci (2010) 1.86
Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors. Exp Neurol (2007) 1.85
Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders. Lancet Neurol (2010) 1.85
ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities. J Pharmacol Exp Ther (2008) 1.81
Distribution of the histaminergic neuron system in the central nervous system of rats; a fluorescent immunohistochemical analysis with histidine decarboxylase as a marker. Brain Res (1984) 1.80
Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. Ann Neurol (2010) 1.80
Adenosine A2A receptor antagonists as new agents for the treatment of Parkinson's disease. Trends Pharmacol Sci (1997) 1.79
Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants. Sci Transl Med (2010) 1.78
A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease. Exp Neurol (2003) 1.75
Dyskinesias following neural transplantation in Parkinson's disease. Nat Neurosci (2002) 1.74
Cannabinoid pharmacology: the first 66 years. Br J Pharmacol (2006) 1.73
Extrasynaptic glutamate spillover in the hippocampus: evidence and implications. Trends Neurosci (1998) 1.72
Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci (2008) 1.71
[11C]DTBZ-PET correlates of levodopa responses in asymmetric Parkinson's disease. Brain (2003) 1.70
Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study. J Neurochem (1991) 1.69
Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Res (1991) 1.67
Receptor subtypes involved in the presynaptic and postsynaptic actions of dopamine on striatal interneurons. J Neurosci (2003) 1.66
Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain (2004) 1.65
Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors. Biol Psychiatry (2007) 1.65
Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol (2005) 1.65
A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis (2004) 1.65
Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Mov Disord (1998) 1.63
CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. J Neurophysiol (2001) 1.63
Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders. Lancet Neurol (2009) 1.61
Levodopa motor complications in Parkinson's disease. Trends Neurosci (2000) 1.58
Aberrant striatal plasticity is specifically associated with dyskinesia following levodopa treatment. Mov Disord (2010) 1.58
Metabotropic glutamate receptors in the basal ganglia motor circuit. Nat Rev Neurosci (2005) 1.57
Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci (2001) 1.57
Norepinephrine: The redheaded stepchild of Parkinson's disease. Biochem Pharmacol (2007) 1.57
Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson's disease. Can J Neurol Sci (1984) 1.57
Regulation of dopamine D1 receptor trafficking and desensitization by oligomerization with glutamate N-methyl-D-aspartate receptors. J Biol Chem (2003) 1.55
L-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice. J Neurochem (2009) 1.53
ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice. Biol Psychiatry (2005) 1.53
Gene targeting--homing in on alpha 2-adrenoceptor-subtype function. Trends Pharmacol Sci (1997) 1.51
Brain substrates for increased drug seeking during protracted withdrawal. Neuropharmacology (2004) 1.50
Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord (2004) 2.90
Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov (2006) 2.23
Altered proteasomal function in sporadic Parkinson's disease. Exp Neurol (2003) 1.91
Etiology and pathogenesis of Parkinson's disease. Mov Disord (2011) 1.80
Parkinson disease: from pathology to molecular disease mechanisms. Free Radic Biol Med (2013) 1.48
Levodopa infusion does not decrease the onset of abnormal involuntary movements in parkinsonian rats. Mov Disord (2012) 1.44
Switching from levodopa to the long-acting dopamine D2/D3 agonist piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP-treated primates. Clin Neuropharmacol (2006) 1.43
Uptake and metabolism of epicatechin and its access to the brain after oral ingestion. Free Radic Biol Med (2002) 1.43
Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. Br J Pharmacol (2011) 1.39
Aggresome-related biogenesis of Lewy bodies. Eur J Neurosci (2002) 1.35
Effect of wild-type or mutant Parkin on oxidative damage, nitric oxide, antioxidant defenses, and the proteasome. J Biol Chem (2002) 1.25
The etiopathogenesis of Parkinson disease and suggestions for future research. Part I. J Neuropathol Exp Neurol (2007) 1.21
Adenosine A2A receptors and Parkinson's disease. Handb Exp Pharmacol (2009) 1.18
Proteasome inhibition causes nigral degeneration with inclusion bodies in rats. Neuroreport (2002) 1.15
Pathogenesis of Parkinson's disease. Mov Disord (2012) 1.13
Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson's disease. Neurosci Lett (2002) 1.11
The acute and the long-term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activation. Eur J Neurosci (2005) 1.07
Proteasomal inhibition causes the formation of protein aggregates containing a wide range of proteins, including nitrated proteins. J Neurochem (2003) 1.05
Osteopontin expression in substantia nigra in MPTP-treated primates and in Parkinson's disease. Brain Res (2006) 0.99
5-s-Cysteinyl-conjugates of catecholamines induce cell damage, extensive DNA base modification and increases in caspase-3 activity in neurons. J Neurochem (2002) 0.99
Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms. J Neurochem (2004) 0.96
Reproducible nigral cell loss after systemic proteasomal inhibitor administration to rats. Ann Neurol (2006) 0.96
In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\ increased motor disability. J Pharmacol Exp Ther (2006) 0.96
Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates. Mov Disord (2005) 0.96
Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease. Exp Neurol (2004) 0.95
New approaches to therapy. Int Rev Neurobiol (2011) 0.92
Markers for dopaminergic neurotransmission in the cerebellum in normal individuals and patients with Parkinson's disease examined by RT-PCR. Eur J Neurosci (2003) 0.91
A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosets. Eur J Neurosci (2005) 0.91
S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole. J Pharmacol Exp Ther (2004) 0.90
Morphological changes in serotoninergic neurites in the striatum and globus pallidus in levodopa primed MPTP treated common marmosets with dyskinesia. Neurobiol Dis (2010) 0.89
Oxidative stress and Parkinson's disease. Handb Clin Neurol (2007) 0.89
Pramipexole protects against MPTP toxicity in non-human primates. J Neurochem (2006) 0.89
Current development of acupuncture research in Parkinson's disease. Int Rev Neurobiol (2013) 0.88
Continuous subcutaneous infusion of pramipexole protects against lipopolysaccharide-induced dopaminergic cell death without affecting the inflammatory response. Exp Neurol (2008) 0.88
Effect of overexpression of wild-type or mutant parkin on the cellular response induced by toxic insults. J Neurosci Res (2005) 0.87
The etiopathogenesis of Parkinson disease and suggestions for future research. Part II. J Neuropathol Exp Neurol (2007) 0.86
Age-associated changes in protein oxidation and proteasome activities in rat brain: modulation by antioxidants. Biochem Biophys Res Commun (2005) 0.86
Interference with ubiquitination causes oxidative damage and increased protein nitration: implications for neurodegenerative diseases. J Neurochem (2004) 0.86
A comparison of changes in proteasomal subunit expression in the substantia nigra in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. Brain Res (2010) 0.85
3,4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates. J Neurosci (2003) 0.85
The timing of administration, dose dependence and efficacy of dopa decarboxylase inhibitors on the reversal of motor disability produced by L-DOPA in the MPTP-treated common marmoset. Eur J Pharmacol (2010) 0.85
Differential toxicity of 6-hydroxydopamine in SH-SY5Y human neuroblastoma cells and rat brain mitochondria: protective role of catalase and superoxide dismutase. Neurochem Res (2012) 0.85
Lipopolysaccharide-induced nigral inflammation leads to increased IL-1β tissue content and expression of astrocytic glial cell line-derived neurotrophic factor. Neurosci Lett (2012) 0.84
The monoamine reuptake blocker brasofensine reverses akinesia without dyskinesia in MPTP-treated and levodopa-primed common marmosets. Mov Disord (2002) 0.84
The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets. Eur J Pharmacol (2006) 0.84
Proteasomal dysfunction induced by 4-hydroxy-2,3-trans-nonenal, an end-product of lipid peroxidation: a mechanism contributing to neurodegeneration? J Neurochem (2002) 0.83
When do levodopa motor fluctuations first appear in Parkinson's disease? Eur Neurol (2010) 0.83
The RGD-containing peptide fragment of osteopontin protects tyrosine hydroxylase positive cells against toxic insult in primary ventral mesencephalic cultures and in the rat substantia nigra. J Neurochem (2010) 0.83
An immunohistochemical and stereological analysis of PSI-induced nigral neuronal degeneration in the rat. J Neurochem (2009) 0.82
Effects of the adenosine A2A antagonist istradefylline on cognitive performance in rats with a 6-OHDA lesion in prefrontal cortex. Psychopharmacology (Berl) (2013) 0.82
Osteopontin (Eta-1) is present in the rat basal ganglia. Brain Res Mol Brain Res (2004) 0.81
Induction and expression of abnormal involuntary movements is related to the duration of dopaminergic stimulation in 6-OHDA-lesioned rats. Eur J Neurosci (2011) 0.81
Increased neuropeptide Y mRNA expression in striatum in Parkinson's disease. Brain Res Mol Brain Res (2003) 0.81
Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus). Exp Neurol (2003) 0.81
A yeast two-hybrid screen reveals that osteopontin associates with MAP1A and MAP1B in addition to other proteins linked to microtubule stability, apoptosis and protein degradation in the human brain. Eur J Neurosci (2012) 0.81
Alterations in m-RNA expression for Cu,Zn-superoxide dismutase and glutathione peroxidase in the basal ganglia of MPTP-treated marmosets and patients with Parkinson's disease. Brain Res (2003) 0.81
Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation. Mov Disord (2002) 0.80
Induction of Mycobacterium avium proteins upon infection of human macrophages. Proteomics (2004) 0.80
The effect of nNOS inhibitors on toxin-induced cell death in dopaminergic cell lines depends on the extent of enzyme expression. Brain Res (2011) 0.79
Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with levodopa. Mov Disord (2002) 0.79
A major metabolite of bupropion reverses motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets. Behav Pharmacol (2011) 0.79
Expression of integrin and CD44 receptors recognising osteopontin in the normal and LPS-lesioned rat substantia nigra. Eur J Neurosci (2013) 0.79
Osteopontin expression in activated glial cells following mechanical- or toxin-induced nigral dopaminergic cell loss. Exp Neurol (2007) 0.79
Dopamine reuptake inhibition and failure to evoke dyskinesia in MPTP-treated primates. Eur J Pharmacol (2002) 0.79
The novel adenosine A2a antagonist ST1535 potentiates the effects of a threshold dose of l-dopa in unilaterally 6-OHDA-lesioned rats. Brain Res (2006) 0.79
Proteasomal abnormalities in cortical Lewy body disease and the impact of proteasomal inhibition within cortical and cholinergic systems. J Neural Transm (Vienna) (2008) 0.79
Loss of locus coeruleus noradrenergic neurons alters the inflammatory response to LPS in substantia nigra but does not affect nigral cell loss. J Neural Transm (Vienna) (2014) 0.79
Dopamine, but not norepinephrine or serotonin, reuptake inhibition reverses motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates. J Pharmacol Exp Ther (2002) 0.78
Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naïve MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure. Mov Disord (2003) 0.78
Effect of 5-HT1B/D receptor agonist and antagonist administration on motor function in haloperidol and MPTP-treated common marmosets. Pharmacol Biochem Behav (2004) 0.78
Proteasome inhibition leads to early loss of synaptic proteins in neuronal culture. J Neural Transm (Vienna) (2012) 0.78
Expression of catechol-O-methyltransferase in the brain and periphery of normal and MPTP-treated common marmosets. J Neural Transm (Vienna) (2009) 0.78
The administration of entacapone prevents L-dopa-induced dyskinesia when added to dopamine agonist therapy in MPTP-treated primates. Exp Neurol (2007) 0.78
Effect and mechanism of acupuncture on Alzheimer's disease. Int Rev Neurobiol (2013) 0.77
Antidepressant-like activity of the adenosine A(2A) receptor antagonist, istradefylline (KW-6002), in the forced swim test and the tail suspension test in rodents. Pharmacol Biochem Behav (2013) 0.77
The distribution of copper, zinc- and manganese-superoxide dismutase, and glutathione peroxidase messenger ribonucleic acid in rat basal ganglia. Biochem Pharmacol (2002) 0.77
The effects of dose and route of administration of PSI on behavioural and biochemical indices of neuronal degeneration in the rat brain. Brain Res (2010) 0.77
Antidepressant activity of the adenosine A2A receptor antagonist, istradefylline (KW-6002) on learned helplessness in rats. Psychopharmacology (Berl) (2014) 0.77
Design, synthesis and biological evaluation of peptide derivatives of L-dopa as anti-parkinsonian agents. Bioorg Med Chem Lett (2013) 0.76
The dopamine D(2) receptor partial agonist aplindore improves motor deficits in MPTP-treated common marmosets alone and combined with L-dopa. J Neural Transm (Vienna) (2009) 0.76
Increased osteopontin expression following intranigral lipopolysaccharide injection in the rat. Eur J Neurosci (2005) 0.76
Adenosine A₂A-receptor antagonist istradefylline enhances the motor response of L-DOPA without worsening dyskinesia in MPTP-treated common marmosets. J Pharmacol Sci (2014) 0.76
Decreased expression of l-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets. Exp Neurol (2006) 0.76
Pardoprunox reverses motor deficits but induces only mild dyskinesia in MPTP-treated common marmosets. Mov Disord (2010) 0.76
Non-motor features of Parkinson disease. Nat Rev Neurosci (2017) 0.76
Effects of short- and long-term (--)-deprenyl administration on mRNA for copper, zinc- and manganese-superoxide dismutase and glutathione peroxidase in rat brain. Brain Res (2002) 0.75
Antimycobacterial calixarenes enhance innate defense mechanisms in murine macrophages and induce control of Mycobacterium tuberculosis infection in mice. Infect Immun (2004) 0.75
A cup of coffee a day keeps dyskinesia away? Mov Disord (2013) 0.75
The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates. Mov Disord (2004) 0.75
Proteomic analysis of striatum from MPTP-treated marmosets (Callithrix jacchus) with L-DOPA-induced dyskinesia of differing severity. J Mol Neurosci (2013) 0.75
Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP-treated common marmosets. Mov Disord (2010) 0.75
New directions. Synapse (2013) 0.75
Lipophilicity plays a major role in modulating the inhibition of monoamine oxidase B by 7-substituted coumarins. Chem Biodivers (2006) 0.75
Inhibition of i-NOS but not n-NOS protects rat primary cell cultures against MPP(+)-induced neuronal toxicity. J Neural Transm (Vienna) (2014) 0.75
Plasma levels of rotigotine and the reversal of motor deficits in MPTP-treated primates. Behav Pharmacol (2007) 0.75
Antiparkinsonian activity of L-propyl-L-leucyl-glycinamide or melanocyte-inhibiting factor in MPTP-treated common marmosets. Mov Disord (2007) 0.75
Benserazide dosing regimen affects the response to L-3,4-dihydroxyphenylalanine in the 6-hydroxydopamine-lesioned rat. Behav Pharmacol (2012) 0.75
Unilateral pallidotomy in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets exhibiting levodopa-induced dyskinesia. Eur J Neurosci (2005) 0.75
Design, synthesis and biological evaluation of L-dopa amide derivatives as potential prodrugs for the treatment of Parkinson's disease. Eur J Med Chem (2010) 0.75
Role of inducible nitric oxide synthase in N-methyl-d-aspartic acid-induced strio-nigral degeneration. Brain Res (2004) 0.75